Outpace Bio™* programs cells to make the right decisions to beat cancer.

The Problem: The precise geometry of antigen-receptor interactions determines the potency of engineered immune cells when fighting cancer. Existing proteins have not provided the flexibility needed to maximize immune cell activity.

Our Solution: The OUTSPACER™ library contains fully human sequences that maximize CAR T cell function, leading to more potent killing of cancer cells. With OUTSPACER™ technology, we can create finely tuned CAR designs that achieve optimal immunological synapse geometry to maximize efficacy.
‍
Our diverse OUTSPACER™ library allows us to optimize activity for a wide range of binders and antigen pairs.

The Problem: Cancer cells, together with the immune cells that should be targeting them, produce signaling proteins that turn off the immune response. This dysfunctional microenvironment allows cancer to grow and spread. Pro-inflammatory cytokines, for example, could overcome the TME but pose a significant safety risk to patients when delivered systemically given their potency.
‍
‍Our Solution: Cell therapies with OUTSMART™ technology produce designed proteins, such as cytokines, inside the tumor and keep them there. With OUTSMART™, the cell therapy bolsters its own activity while also recruiting helpful bystander cells to achieve efficacy without compromising safety.

‍OUTSMART™ uses novel promoter elements to regulate gene expression and protein design to customize which cells and signaling pathways are activated.

The Problem: Immune cells naturally turn off when fighting cancer, limiting the effectiveness of current engineered cell therapies. This can lead to cancer progression and relapse.

Our Solution:  OUTLAST™ technology reprograms cell therapies to make better decisions inside patients with the goal of achieving a durable clinical response. With OUTLAST™, individual cells regulate themselves without the need for co-therapies to rest and reactivate as needed.

OUTLAST™ uses novel promoter elements to regulate gene expression and novel designed targeted degraders to regulate protein function.

The Problem: Engineered TCRs mispair with native TCRs; other approaches require complicated gene editing.

Our Solution: Protein design enables strong surface expression of properly paired α/β chains without the need for gene knockout or knock-in.

Recombinant TCRs can mispair with native TCRs, limiting efficacy. OUTMATCH™ favors correct pairing of the engineered TCR α/β chains, delivering strong surface expression without endogenous TCR knockout.

The Problem: Existing solutions trade off between cost and safety, and existing transgenes cannot drive efficacy in lymphoreplete patients.

Our Solution: Scalable in vivo delivery with durable efficacy via OUTTech transgenes, and durable safety via increased specificity, reduced systemic activation, and no lymphodepletion.

Efficacy is preserved via OUTSMART™, OUTLAST™ and other technologies in the lymphoreplete setting. Safety is driven by OUTDRIVE™ specificity, reduced systemic activation, and no lymphodepletion. Cost is reduced by an off-the-shelf product with higher transduction efficiency and lower required doses.

The Problem: Powerful cell therapies require advanced safety features and technologies to help monitor both manufacturing quality and how cell therapies function inside patients.

Our Solution: With EGFRopt™ technology, cell therapies can be safely controlled by antibodies that target the EGF receptor. This allows them to be deactivated quickly if needed.

EGFRopt™ is a fully human control technology that responds to cetuximab. In vivo studies demonstrate faster & more complete ablation of CAR activity.

‍EGFRopt™ can also be used for other applications including cell selection and quality control during manufacturing.